Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Scott Kopetz(The University of Texas MD Anderson Cancer Center), Josep Tabernero(Deaconess Hospital), Sergey Orlov(St Petersburg University), Van K. Morris(The University of Texas MD Anderson Cancer Center), Yong Sang Hong(Ulsan College), Elena Élez(Vall d'Hebron Hospital Universitari), Christina Guo(Peter MacCallum Cancer Centre), Rona Yaeger(Memorial Sloan Kettering Cancer Center), Ashwin Gollerkeri(Peter MacCallum Cancer Centre), Michael D. Pickard(Peter MacCallum Cancer Centre), Lisa Anderson(Peter MacCallum Cancer Centre), Sara Lonardi(Istituto Oncologico Veneto), Neeltje Steeghs(Peter MacCallum Cancer Centre), Michael Braun(Peter MacCallum Cancer Centre), Fotios Loupakis(Azienda Ospedaliera Universitaria Pisana), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Axel Grothey(Campbell Clinic), Takayuki Yoshino(University of Tsukuba), Line Schmidt Tarpgaard(Odense University Hospital), Harpreet Wasan(Hammersmith Hospital), Asha Krishnan(Memorial Sloan Kettering Cancer Center), Per Pfeiffer(University of Southern Denmark), Jeroen Dekervel(Universitair Ziekenhuis Leuven), Tormod Kyrre Guren(Oslo University Hospital), Janna Christy‐Bittel(Peter MacCallum Cancer Centre), Jayesh Desai(Peter MacCallum Cancer Centre), Pilar García‐Alfonso(Hospital General Universitario Gregorio Marañón), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Christopher Hunt Keir(Peter MacCallum Cancer Centre), Victor Sandor(Peter MacCallum Cancer Centre), Jan H.M. Schellens(Utrecht University), Tae-Won Kim(Ulsan College), Kati Maharry(Peter MacCallum Cancer Centre)
Cited by 1,459
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k